Cartalax is a tripeptide bioregulator targeting cartilage and musculoskeletal tissue. Developed as part of the Russian bioregulatory peptide research program.
What Is Cartalax?
- Type: Synthetic tripeptide bioregulator
- Target Tissue: Cartilage, spine, musculoskeletal system
- Sequence: Ala-Glu-Asp (Alanine - Glutamic acid - Aspartic acid)
- Related to: Sigumir (similar target tissue)
Mechanism of Action
Like other Khavinson peptides:
- Gene expression modulation in target cells
- Stimulates chondrocyte activity
- Supports extracellular matrix production
- May slow degenerative cartilage changes
Primary Use Cases
- Spinal disc degeneration
- Osteoarthritis — especially spine and weight-bearing joints
- Age-related cartilage wear
- Post-injury cartilage support
- Athletic joint preservation
Cartalax vs Sigumir
Both target cartilage, but:
| Feature | Cartalax | Sigumir |
|---|---|---|
| Primary focus | Spine/discs | Joints general |
| Peptide | Ala-Glu-Asp | Glu-Asp-Leu |
| User reports | Spine emphasis | Knee/hip emphasis |
| Stacking | Often together | Often together |
Many users combine both for comprehensive cartilage support.
Dosing Protocol
Oral Capsules
| Parameter | Recommendation |
|---|---|
| Dose | 10-20 mg (1-2 capsules) |
| Frequency | 1-2x daily |
| Timing | Before meals |
| Duration | 10-30 days |
| Cycling | Repeat 2-3x/year |
Injectable
- 10-20 mcg subcutaneous
- Once daily for 10-20 days
What to Expect
During Course (10-30 days)
- Gradual effects
- Some report reduced stiffness
- Back discomfort may improve
After Course
- Effects may persist months
- Bioregulatory changes are cumulative
- Repeated courses build on previous
Timeline
- Don’t expect overnight changes
- Assess after completing full course
- Compare symptoms month-to-month
Side Effects
Minimal reported:
- Generally well-tolerated
- Occasional mild digestive discomfort
- No significant adverse effects in literature
Stacking Options
Cartilage-Focused Stack:
- Cartalax + Sigumir (different sequences, same target)
- Add BPC-157 for inflammation/healing
- Collagen peptides for structural support
Full Musculoskeletal Stack:
- Cartalax (cartilage)
- Sigumir (joints)
- TB-500 (muscle/tendon)
- BPC-157 (inflammation/healing)
Sourcing
- Russian suppliers primarily
- Some European peptide companies
- Quality verification important — ask for testing
The Honest Take
Cartalax occupies the same space as Sigumir — interesting bioregulatory peptide with limited Western validation. If you have spinal disc issues or degenerative joint conditions and standard treatments have plateaued, these bioregulators may be worth exploring. But manage expectations — regenerating cartilage is hard, and no peptide is a guaranteed solution.
For established joint peptides, see BPC-157 for Knee Pain. For the full joint stack, see BPC-157 + TB-500.